Premium
P3‐453: Rationale and strategy for thalidomide as a BACE 1 inhibitor for a phase II randomized clinical trial in mild‐to‐moderate Alzheimer's disease
Author(s) -
Sabbagh Marwan N.,
Nural Hikmet,
He Ping,
Sirrel Sherye,
Belden Christine,
Liebsack Carolyn,
Li Rena,
Shen Yong
Publication year - 2010
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2010.05.1996
Subject(s) - thalidomide , tolerability , clinical trial , donepezil , placebo , medicine , amyloid precursor protein secretase , pharmacology , amyloid precursor protein , disease , dementia , oncology , alzheimer's disease , adverse effect , pathology , alternative medicine , multiple myeloma